Singapore - engelska - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - ustekinumab - injection, solution - 90mg/1ml - ustekinumab 90mg/1ml

Singapore - engelska - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - plerixafor - injection, solution - 20mg/ml - plerixafor 20mg/ml

Irland - engelska - HPRA (Health Products Regulatory Authority)

jurox (ireland) limited - alfaxalone - solution for injection - 10 milligram(s)/millilitre - alfaxalone

Israel - engelska - Ministry of Health

glaxo smith kline (israel) ltd - mepolizumab - powder for solution for injection - mepolizumab 100 mg - mepolizumab - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patientschronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with corticosteroids and surgery in the last 10 years do not provide adequate disease control.eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (egpa).hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Malta - engelska - Medicines Authority

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - daptomycin - powder for solution for injection/infusion - daptomycin 350 mg - antibacterials for systemic use

Malta - engelska - Medicines Authority

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - daptomycin - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use

Australien - engelska - Department of Health (Therapeutic Goods Administration)

medison pharma australia pty ltd - tebentafusp, quantity: 0.2 mg/ml - injection, concentrated - excipient ingredients: citric acid monohydrate; water for injections; mannitol; trehalose dihydrate; polysorbate 20; dibasic sodium phosphate - kimmtrak is indicated for the treatment of hla-a02 01-positive adult patients with unresectable or metastatic uveal melanoma.

Irland - engelska - HPRA (Health Products Regulatory Authority)

merck serono limited - somatropin, recombinant human growth hormone - pdr+solv for soln for inj - 8 milligram - somatropin and somatropin agonists

Australien - engelska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: sodium acetate trihydrate; sodium chloride; water for injections; glacial acetic acid - levetiracetam concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible. use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and, add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - injection, concentrated - excipient ingredients: glacial acetic acid; sodium chloride; water for injections; sodium acetate trihydrate - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.